Liang Mingxing, Fei Yinjiao, Wang Yalin, Chen Wenquan, Liu Zhen, Xu Di, Shen Hongyu, Zhou Honglei, Tang Jinhai
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
School of Clinical Medicine, Xuzhou Medical University, Xuzhou, China.
Front Genet. 2023 Feb 27;14:1077126. doi: 10.3389/fgene.2023.1077126. eCollection 2023.
is a recently discovered protein-coding gene. Here, pan-cancer analysis was conducted to determine the expression patterns of and its impact on immune response, gene mutation, and possible molecular biological mechanisms in different tumors, together with investigating its potential usefulness for cancer prognosis. Data on expression and mutations were downloaded from TCGA and GTEx databases. Clinical survival data from TCGA were used to analyze the prognostic value of . TIMER and ESTIMATE algorithms were used to assess correlations between and tumor-infiltrating immune cells, immune cytokines, and immune scores. BOLA2B was found to be highly expressed at both mRNA and protein levels in multiple tumors, where it was associated with worse overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in all cancers apart from ovarian cancer. was also found to be positively correlated with copy number variation (CNV), and mutations in , and were found to influence expression. Post-transcriptional modifications, including m5C, m1A, and m6A, were observed to regulate expression in all cancers. Functional analysis showed that was enriched in pathways associated with iron-sulfur cluster formation, mTOR-mediated autophagy, and cell cycle inhibition. Decreased expression induced the proliferation of breast cancer cells and G2/M cell cycle arrest. was found to be highly expressed in malignant tumors and could be used as a biomarker of poor prognosis in multiple cancers. Further investigation into 's role and molecular functions in cancer would provide new insights for cancer diagnosis and treatment.
是一个最近发现的蛋白质编码基因。在此，进行了泛癌分析，以确定其表达模式及其对不同肿瘤中免疫反应、基因突变和可能的分子生物学机制的影响，并研究其对癌症预后的潜在有用性。从TCGA和GTEx数据库下载了其表达和突变数据。使用来自TCGA的临床生存数据来分析其预后价值。使用TIMER和ESTIMATE算法评估其与肿瘤浸润免疫细胞、免疫细胞因子和免疫评分之间的相关性。发现BOLA2B在多种肿瘤的mRNA和蛋白质水平上均高表达，在除卵巢癌以外的所有癌症中，它与较差的总生存期（OS）、疾病特异性生存期（DSS）和无进展生存期（PFI）相关。还发现其与拷贝数变异（CNV）呈正相关，并且其突变以及其他相关基因的突变被发现会影响其表达。观察到包括m5C、m1A和m6A在内的转录后修饰在所有癌症中调节其表达。功能分析表明，它在与铁硫簇形成、mTOR介导的自噬和细胞周期抑制相关的途径中富集。其表达降低诱导乳腺癌细胞增殖并导致G2/M细胞周期停滞。发现其在恶性肿瘤中高表达，并且可作为多种癌症预后不良的生物标志物。对其在癌症中的作用和分子功能的进一步研究将为癌症诊断和治疗提供新的见解。
